STOCK TITAN

Neuronetics Inc - STIM STOCK NEWS

Welcome to our dedicated news page for Neuronetics (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neuronetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neuronetics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
-
Rhea-AI Summary
Neuronetics reports Q2 2023 revenue of $17.6 million, an 8% increase YoY. U.S. treatment session revenue increased 9%. Shipped 54 NeuroStar systems. BCBS of Michigan reduces antidepressant attempts for TMS eligibility. Aetna allows nurse practitioners to prescribe TMS. Received 510(k) clearance for OCD MT cap technology. Full-year revenue expected to be between $69.0 million and $73.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
conferences earnings
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) announced that Aetna's healthcare policy update increases access to the Company’s NeuroStar® Advanced Therapy for patients with major depressive disorder (MDD). This update allows TMS treatment to be ordered and conducted under the supervision of behavioral health nurse practitioners, removing the previous requirement of a four-month psychotherapy trial before treatment eligibility. Aetna's policy change aims to help people earlier in their treatment journey, recognizing the need to alleviate access barriers for mental health treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
Neuronetics Inc

Nasdaq:STIM

STIM Rankings

STIM Stock Data

128.55M
21.29M
6.62%
65.25%
0.32%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Malvern

About STIM

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.